1. Home
  2. AVIR

as of 12-11-2025 10:26am EST

$3.19
+$0.03
+0.95%
Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Chart Type:
Time Range:
Founded: 2012 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 236.7M IPO Year: 2020
Target Price: $6.00 AVG Volume (30 days): 415.4K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.77 EPS Growth: N/A
52 Week Low/High: $2.46 - $4.02 Next Earning Date: 11-12-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered AVIR Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 16 hours ago

AI Recommendation

hold
Model Accuracy: 71.43%
71.43%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest Atea Pharmaceuticals Inc. News

AVIR Breaking Stock News: Dive into AVIR Ticker-Specific Updates for Smart Investing

All AVIR News

Share on Social Networks: